suMM:ARY Propranolol, a non-selective ,B blocker, was administered orally in therapeutic doses. The effects of a single dose (160 mg) and one week's treatment (80 mg twice a day) on platelet function were compared in healthy young subjects. There were no significant changes in circulating platelet aggregates, template bleeding time, platelet factor 3 availability and thromboxane f2 (TXP2) generation. Platelet aggregation responses as assessed by angle of slope and maximal percentage aggregation (all agonists) and lag phase (collagen) showed no changes of biological importance, although minor changes reaching significance were observed with some agonists. These findings suggest that propranolol does not significantly affect platelet function when taken at doses commonly encountered in clinical practice.
D H PAMPHILON, R J BOON, A G PRENTICE, A ROZKOVEC* From the Departments of Haematology and *Cardiology, Derriford Hospital, Plymouth suMM:ARY Propranolol, a non-selective ,B blocker, was administered orally in therapeutic doses. The effects of a single dose (160 mg) and one week's treatment (80 mg twice a day) on platelet function were compared in healthy young subjects. There were no significant changes in circulating platelet aggregates, template bleeding time, platelet factor 3 availability and thromboxane f2 (TXP2) generation. Platelet aggregation responses as assessed by angle of slope and maximal percentage aggregation (all agonists) and lag phase (collagen) showed no changes of biological importance, although minor changes reaching significance were observed with some agonists. These findings suggest that propranolol does not significantly affect platelet function when taken at doses commonly encountered in clinical practice.
Beta blockers reduce the risk of mortality after myocardial infarction,'2 but the underlying reasons for this are unknown. Platelets play a part in the pathogenesis of coronary events,3 and the attendant hyperreactivity of platelets can be normalised by the use of propranolol.4 In vitro and in vivo studies of the action of f blockers on platelets, however, have yielded conflicting results,"'0 which can be partly explained by differences in dose and the ancillary properties ofthe drugs studied. Theoretical consideration of platelet adrenoreceptors indicates that nonselective f blockers such as propranolol may enhance aggregatory responses,'0 potentially undesirable in myocardial infarction. Platelet aggregation and other measurements of platelet activation are unaffected by the selective f blocker metoprolol." We undertook a study to determine whether a therapeutic dose of propranolol would affect standard tests of platelet function in a group of healthy young subjects.
Subjects and methods
Seventeen healthy volunteers aged 18 to 37 years took part. Informed consent was obtained in each case and approval was obtained from the hospital ethical committee. No substances with antiplatelet activity in the 10 days preceding or during the study period were allowed. On each occasion blood was taken from an antecubital vein without stasis using a 21G butterfly Accepted for publication 31 March 1989 cannula after 15 minutes of rest. Subjects were fasted overnight and remained so until after the sample at 1200 hours. Following a control sample at 0900 hours the eight subjects of group 1 took a single dose of 160 mg of propranolol by mouth and further samples were obtained at 1200 and 1500 hours on the same day and at 0900 hours on day 2. The nine participants in group 2 continued to take propranolol 80 mg twice a day for an additional seven days and further samples were taken before the first dose and at 0900 hours on days 1, 2, 8, 9, and at 1200 hours on days 1 and 8.
In group 1 we measured the template bleeding time (Simplate, General Diagnostics), circulating platelet aggregates,'2 and full blood count, including platelet variables using the Coulter S Plus 4. Whole blood anticoagulated in the ratio of 9:1 with 0-129M citrate was prepared for platelet aggregation studies and responses tested with adenosine diphosphate (ADP) (2, 5, and 10 pM), collagen (4 ug/ml), adrenalin (10 uM), noradrenalin (10 pM), arachidonic acid (0 5 mg/ml) and ristocetin (1 5 mg/ml) (figures given as the final concentration) using a Platelet Aggregation Profiler (model PAP4, Bio-Data Corporation). The results were expressed as angle of slope (all agonists), lag phase (collagen only), and maximal percentage amplitude of aggregation (all agonists). Samples for cyclic adenosine monophosphate (cAMP) assay were prepared and stored as previously described,'3 and subsequently assayed using the kit supplied by Amersham International plc. The assay was validated by showing loss of measurable cAMP activity after treatment with phosphodiesterase. Collagen 4 ug/ml 46 (10) 38 (13) 40 (9) 43 (8) 43 (13) 44 (7) Arachidonic acid 0-5 mg/ml 35 (8) 30 (5) 27 (6) 31 (6) 31 (9) 32 (3) ADP 10puM
46 (9) 35 (11) 43 (8) 41 (8) 41 (8) 43 (6) Adrenaline 10 sM
19 (6) 15 (7) 18 (4) 20 (7) 16 (5) 18 (6) Collagen (lag phase) (s)
29 (10) 31 (13) 31 (11) 26 (12) 30 (9) Values given as mean (± SD)
For group 2 subjects a more selected range of significantly after a single dose of propranolol when platelet agonists was used (table 1 ). To facilitate the tested at three and 24 hours. In two subjects the simultaneous testing of large numbers of sample baseline bleeding time was 12 and 13 minutes, respeccuvettes, ADP was included only at the 10 MM dose tively (normal range for template method two to 10 while ristocetin and noradrenaline were omitted. minutes), but this alone does not indicate abnormal Additional subsamples were taken from replicate platelet function,'6 and it was in the normal range cuvettes in six ofthe subjects one minute after maximal thereafter. The remainder of the platelet function tests aggregation in response to the addition of either were also entirely normal. A small but significant collagen 4 pg/ml or arachidonic acid 0-5 mg/ml. These change in platelet aggregatory responses to collagen were immediately anticoagulated with indomethacin (p < 0-05), noradrenaline (p < 0-05), and adrenaline 50 pM and edetic acid 5 mM on dry ice. After (p < 0.01) was seen by day 2 when the angle of slope centrifugation, samples were stored at -20°C and was analysed (table 2). The lag phase for collagen was TXB2 generation was measured by radioimmunoassay unaffected. Reduction in maximal amplitude of (Amersham International plc). Platelet factor 3 (PF3) aggregation was also seen with collagen (p < 0-01) availability was measured by a standard and noradrenaline (p < 0-05) in this group (data not method.'4 The results were analysed by Friedman's shown). The changes were not striking, and these two way analysis of variance for non-parametric observations do not seem to have any biological data. '5 importance. Resting cAMP concentrations and circulating platelet aggregate ratios were unaffected.
Results
Similarly, in group 2 subjects no change in the circulating platelet aggregate ratio was observed. PF3 In group 1 subjects no change was seen in the mean availability was normal and the release of TXB2 in platelet volume or other variables measured by the response to stimulation of platelet rich plasma with Coulter S Plus 4. The bleeding time did not change either collagen or arachidonic acid was not inhibited. A;gregation responses-slope:
Ristocetin 1-5 mg/ml 34 (5) 32 (3) 36 (5) 28 (9) Collagen 4 jg/ml 42 (6) 44 (8) 47 (6) 37 (4)* Arachidonic acid 0-5 mg/ml 26 (8) 30 (5) 26 (7) 22 (9) ADP 2puM
8 (5) 11 (5) 12 (5) 12 (4) ADP 5puM
41 (7) 43 (6) 40 (3) 38 (5) ADP 10uM 40 (8) 45 (4) 42 (6) 40 (7) Adrenaline 10 pM 21 (5) 21 (6) 22 (6) 22 (6)t Noradrenaline 10 pM 18 (6) 19 (9) 19 (8) 18 (3)* Collagen (lag phase (s)
29 (11) 25 (10) 23 (5) 21 (8) cAMP (pmol/1I platelets) (table 1) , the maximal percentage amplitude in response to ADP 10upM showed a small but significant reduction during one week of treatment (p < 0.05) (data not shown). Statistical analysis of aggregation responses over the first 24 hours of treatment in this group did not indicate a significant change (group 1). Lower doses of ADP were not included here and a more pronounced change might have been seen at 2 or 5 pM concentrations.
Discussion
In vitro studies of propranolol in concentrations of 10-100 pM have shown that human platelet aggregation responses are inhibited.9"' This "membranestabilising" effect seems to be because of the drug's lipophilic nature and independent of the adrenoreceptor action." 8 These concentrations exceed those achieved in plasma when therapeutic doses of propranolol are given by a factor of 10-1000."'9 Similar conclusions have been drawn from studies of other f blockers.1' The effects of f blockers on lipid membranes are a specific function of the structure of each drug.2'
Inhibition of TXB2 formation can prevent platelet aggregation'; in our study there was no reduction with a daily dose of 160 mg of propranolol. Campbell et al, in a group of hypertensive subjects, also found no effect at this dose. When 640 mg of propranolol was given daily, however, TXB2 generation was noticeably inhibited. 23 In a group of 14 subjects with coronary artery disease taking a mean dose of 231 mg of propranolol daily, Mehta and Mehta found reduced TXB2 generation compared with untreated patients.6
In seven healthy male subjects in vitro thromboxane production increased threefold 30 minutes after adrenaline infusion. This increase was considerably reduced by pindolol.24 Human platelets are known to possess both a and 1 receptors. The latter are of the ,B-2 type; their stimulation leads to a rise in platelet cAMP and reduction in aggregability.25 Non-selective 13 blockers such as propranolol exert a greater effect on platelets than selective agents, which mainly antagonise 13 receptors." Theoretically propranolol will induce unopposed a activity and should increase the chance of aggregation. This result has been seen in studies where aggregatory responses were measured during administration of either propranolol or timolol.'°" The clinical setting that corresponds to this experimental work is the period immediately following acute myocardial infarction when circulating catecholamines are high, platelet aggregation and thromboxane release are increased, and thrombotic events occur. 26 By reducing background catecholamine activity, however, P blockade may indirectly reduce platelet adrenergic stimulation. Both catecholamine activity and platelet aggregation responses are known to show diurnal variation, and this might explain small variations in carecholamine induced platelet aggregation as sampling occurred at varying times in relation to the dose of propranolol in our study. Although a significant reduction in adrenaline and noradrenaline induced aggregation was observed in the single dose group, there was little evidence of a biologically important change, and no change in aggregation responses was seen during the first 24 hours in group 2 subjects. Furthermore, no changes in platelet responses to catecholamine agonists were seen during one week of study.
The present work is based on resting normal volunteers in whom there was little chance of vascular disease or of raised catecholamine activity. Patients with cardiovascular disease have platelets which are unusually responsive to excitatory stimuli and* a different pattern of response might have been seen. In summary, we found no changes of biological importance in platelet behaviour when studying a group of healthy young adults using propranolol at commonly used daily doses.
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